Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Multiple Cancer Types

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin to determine the safety and maximum tolerated dose.
Lymphoma, Ovarian, Phase I
Berlin, Jordan

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: